To determine the therapeutic effect of nootropic agent Cerebrolysin on patients with mild to moderate Alzheimer’s disease (AD), we searched the Cochrane Library, Medline, PubMed, and Chinese Biomedical Literature Analysis and Retrieval System for Compact Disc (CBMDISC), and communicated with EBEWE Pharmaceutical Ltd, for randomized trials comparing Cerebrolysin with placebo in AD. Available data on clinical global impression, cognitive performance and activities of daily living were extracted from 6 randomized double-blind placebo-controlled clinical trials and combined with standard meta-analysis methods. An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression. Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463–1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD. However, more convincing evidences are needed for the efficacy of Cerebrolysin on the cognitive performance and activities of daily living.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
XA Alvarez R Cacabelos M Laredo V Couceiro C Sampedro M Varela L Corzo L Fernandez-Novoa M Vargas M Aleixandre C Linares E Granizo D Muresanu H Moessler (2006) ArticleTitleA 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease Eur J Neurol 13 43–54 Occurrence Handle16420392 Occurrence Handle10.1111/j.1468-1331.2006.01222.x Occurrence Handle1:STN:280:DC%2BD28%2FjtlSjtg%3D%3D
CY Bae CY Cho K Cho BH Oh KG Choi HS Lee SP Jung (2000) ArticleTitleA double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease J Am Geriatr Soc 48 1566–1571 Occurrence Handle11129744 Occurrence Handle1:STN:280:DC%2BD3M%2FnvVCitw%3D%3D
RJ Boado (2001) ArticleTitleAmplification of blood–brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides Neurosci Res 40 337–342 Occurrence Handle11463479 Occurrence Handle10.1016/S0168-0102(01)00246-2 Occurrence Handle1:CAS:528:DC%2BD3MXltF2js7g%3D
P Eder I Reinprecht E Schreiner G Skofitsch M Windisch (2001) ArticleTitleIncreased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats Histochem J 33 605–612 Occurrence Handle12197668 Occurrence Handle10.1023/A:1016394031947 Occurrence Handle1:CAS:528:DC%2BD38Xltlemtb8%3D
KM Frick DL Price VE Koliatsos AL Markowska (1997) ArticleTitleThe effects of nerve growth factor on spatial recent memory in aged rats persist after discontinuation of treatment J Neurosci 17 2543–2550 Occurrence Handle9065514 Occurrence Handle1:CAS:528:DyaK2sXitV2isL0%3D
DF Muresanu M Rainer H Moessler (2002) ArticleTitleImproved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin J Neural Transm Suppl 62 277–285 Occurrence Handle12456070 Occurrence Handle1:CAS:528:DC%2BD3sXhsFeqtrs%3D
SLT Normand (1999) ArticleTitleMeta-analysis: formulating, evaluating, combining, and reporting Stat Med 18 321–359 Occurrence Handle10070677 Occurrence Handle10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P Occurrence Handle1:STN:280:DyaK1M7mvFyrsQ%3D%3D
M Panisset S Gauthier H Moessler M Windisch InstitutionalAuthorNameCerebrolysin Study Group (2002) ArticleTitleCerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent J Neural Transm 109 1089–1104 Occurrence Handle12111446 Occurrence Handle10.1007/s007020200092 Occurrence Handle1:CAS:528:DC%2BD38XnsFOisLY%3D
E Rockenstein A Adame M Mante G Larrea L Crews M Windisch H Moessler E Masliah (2005) ArticleTitleAmelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound cerebrolysin J Neural Transm 112 269–282 Occurrence Handle15657642 Occurrence Handle10.1007/s00702-004-0181-4 Occurrence Handle1:CAS:528:DC%2BD2MXkvFGhsA%3D%3D
E Rockenstein M Torrance M Mante A Adame A Paulino JB Rose L Crews H Moessler E Masliah (2006) ArticleTitleCerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer’s disease J Neurosci Res 15 1252–1261 Occurrence Handle10.1002/jnr.20818 Occurrence Handle1:CAS:528:DC%2BD28XkvFSgu7s%3D
E Ruether R Rither M Apecechea S Freytag M Windisch (1994) ArticleTitleEfficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT) Pharmacopsychiatry 27 32–40 Occurrence Handle10.1055/s-2007-1014271
E Ruether R Ritter M Apecechea S Freytag R Gmeinbauer M Windisch (2000) ArticleTitleSustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy J Neural Transm 107 815–829 Occurrence Handle10.1007/s007020070061
E Ruether R Husmann E Kinzler E Diabl D Klingler J Spatt R Ritter R Schmidt Z Taneri W Winterer D Koper S Kasper M Rainer H Moessler (2001) ArticleTitleA 28-week, double-blind, placebo-controlled study with Cerebrolysin in patient with mild to moderate Alzheimer’s disease Int Clin Psychopharmacol 16 253–263 Occurrence Handle11552768 Occurrence Handle10.1097/00004850-200109000-00002 Occurrence Handle1:STN:280:DC%2BD3Mrgt1GnsQ%3D%3D
E Ruether XA Alvarez M Rainer H Moessler (2002) ArticleTitleSustained improvement of cognition and global function in patients with moderately severe AD: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin J Neural Transm Suppl 62 265–275 Occurrence Handle12456069 Occurrence Handle1:CAS:528:DC%2BD3sXhsFeqtro%3D
A Seiger A Nordberg H von Holst L Backman T Ebendal I Alafuzoff K Amberla P Hartvig A Herlitz A Lilja (1993) ArticleTitleIntracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy Behav Brain Res 57 255–261 Occurrence Handle8117429 Occurrence Handle10.1016/0166-4328(93)90141-C Occurrence Handle1:STN:280:DyaK2c7mtFyrtw%3D%3D
A Whitehead (2002) Meta-analysis of controlled clinical trial J Wiley Chichester
Sf Xiao H Yan P Yao (2000) ArticleTitleEfficacy of FPF1070 (Cerebrolysin) in patients with Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled trial Clin Drug Invest 19 43–53 Occurrence Handle10.2165/00044011-200019010-00006 Occurrence Handle1:CAS:528:DC%2BD3cXpvFOltA%3D%3D
About this article
Cite this article
Wei, Z., He, Q., Wang, H. et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease. J Neural Transm 114, 629–634 (2007). https://doi.org/10.1007/s00702-007-0630-y
- Keywords: Alzheimer’s disease, dementia, Cerebrolysin, neurotrophic therapy, clinical trials, meta-analysis